-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Downgrades Conmed to Hold, Maintains Price Target to $61

Benzinga·06/12/2025 12:32:17
Listen to the news
Needham analyst Mike Matson downgrades Conmed (NYSE:CNMD) from Buy to Hold and maintains the price target from $61 to $61.